Teva's $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires

0 points · first seen 10h ago · 1 outlet · 0 comments

Samsung Bioepis Teva biosimilar deal announced Monday grants Teva exclusive US rights to two FDA-approved drugs -- RENFLEXIS and ETICOVO -- for up to $420 million, but a federal court's permanent injunction bars ETICOVO from US pharmacies until April 2029, locking the etanercept biosimilar market for Amgen's Enbrel until patent expiry. — Tech Times

save

· share to X · Bluesky · copy link